Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPhase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Clinical Cancer Research, 08/20/09
Badros A et al. – The maximum tolerated dose of vorinostat in study was 400 mg daily for 8 days every 21 days, with bortezomib administered at a dose of 1.3 mg/m2 on days 1, 4, 8, and 11. The promising antimyeloma activity of the regimen in refractory patients merits further evaluation.
Related Articles
Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry
Acta Haematologica, 11/04/09
Relevance Score: 69%
Characteristics of Orbital Multiple Myeloma: A Case Report and Literature Review
Survey of Ophthalmology, 10/23/09
Relevance Score: 69%
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Journal of Clinical Oncology, 10/02/09
Relevance Score: 69%
A randomized phase III study on the effect of thalidomide combined with Adriamycin, dexamethasone (TAD), and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Blood, 11/23/09
Relevance Score: 67%
An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma
Anticancer Research, 11/13/09
Relevance Score: 67%
Today in Myeloproliferative Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan
Bone Marrow Transplantation, 12/10/09
Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells
European Journal of Haematology, 12/10/09
Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival
European Journal of Haematology, 12/10/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
British Journal of Cancer, 12/11/09
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review
Journal of Clinical Oncology, 12/10/09
18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: An economic evaluation
European Journal of Cancer, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor